Safety and Early Signs of Efficacy of IL12-L19L19

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-510841-32-00

Acronym

PH-IL12L19L19-01/19

Enrollment

Registered

2024-03-05

Start date

2020-05-27

Completion date

Unknown

Last updated

2025-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or metastatic carcinomas after previous immune checkpoint blockade therapy

None listed

Sex/Gender

All

Age

18 Years to No maximum

Germany, Italy

None listed

Source: EU CTIS · Data processed: Feb 4, 2026